Neximmune Debt To Equity vs. EBITDA

NEXIDelisted Stock  USD 2.43  0.22  9.95%   
Based on the measurements of profitability obtained from Neximmune's financial statements, Neximmune may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Neximmune's ability to earn profits and add value for shareholders.
For Neximmune profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neximmune to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neximmune utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neximmune's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neximmune over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Please note, there is a significant difference between Neximmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neximmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neximmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Neximmune EBITDA vs. Debt To Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Neximmune's current stock value. Our valuation model uses many indicators to compare Neximmune value to that of its competitors to determine the firm's financial worth.
Neximmune is rated below average in debt to equity category among its peers. It is rated below average in ebitda category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Neximmune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neximmune's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Neximmune EBITDA vs. Debt To Equity

Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Neximmune

D/E

 = 

Total Debt

Total Equity

 = 
0.02 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Neximmune

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(28.17 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Neximmune EBITDA Comparison

Neximmune is currently under evaluation in ebitda category among its peers.

Neximmune Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Neximmune, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neximmune will eventually generate negative long term returns. The profitability progress is the general direction of Neximmune's change in net profit over the period of time. It can combine multiple indicators of Neximmune, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.

Neximmune Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Neximmune. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neximmune position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neximmune's important profitability drivers and their relationship over time.

Use Neximmune in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neximmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neximmune will appreciate offsetting losses from the drop in the long position's value.

Neximmune Pair Trading

Neximmune Pair Trading Analysis

The ability to find closely correlated positions to Neximmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neximmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neximmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neximmune to buy it.
The correlation of Neximmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neximmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neximmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neximmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Neximmune position

In addition to having Neximmune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aggressive Funds Thematic Idea Now

Aggressive Funds
Aggressive Funds Theme
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in Neximmune Pink Sheet

If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals